News ArticleWockhardt Reports Rs. 73 Crore Profit After Tax in Q2 FY27 on 24% Revenue Growth Fueled by Biotech Surge
Strong growth in Biotech segment by 68% and Emerging Markets drives revenue to Rs. 969 crore; US FDA approves novel antibiotic Zaynich
Wockhardt Limited reported a 24% revenue increase to Rs. 969 crore in Q2 FY27, posting a PAT of Rs. 73 crore. Strong growth in Biotech operations by 68% and Emerging Markets fueled overall performance. The company continued successful launches and gained US FDA approval for its novel antibiotic Zaynich.
Wockhardt Limited
General / Other
Wockhardt Limited announced a profit after tax (PAT) of Rs. 73 crore for the second quarter of fiscal year 2026-27, achieving 24% revenue growth to Rs. 969 crore compared to the previous year. The company’s Biotech operations grew by 68%, while Emerging Markets revenues increased by 52%, contributing strongly to overall performance.
The company’s EBITDA for Q2 FY27 stood at Rs. 165 crore with a margin of 17.0%, excluding pre-launch expenses for Zaynich, the adjusted EBITDA was Rs. 201 crore. For the half year ended September 30, 2026, Wockhardt posted 25% revenue growth to Rs. 1,898 crore and a 35% increase in EBITDA to Rs. 353 crore.
Biotech operations reached Rs. 252 crore revenue in the quarter with a 68% increase year-over-year, driven by emerging market growth of approximately 110% in the first half. Key markets contributing to this were Brazil, Thailand, Egypt, Algeria and LATAM.
The India branded business grew 8% to Rs. 146 crore in Q2, supported by diabetic therapies, new chemical entities like EMROK, and regenerative derma products. The UK market recorded 4% growth to GBP 28 million.
The company’s novel antibiotic Zaynich received US FDA approval in May 2026 for complicated urinary tract infections, marking it as the first India-discovered drug approved by the US FDA. Regulatory review with EMA is ongoing, and marketing authorization application has been accepted.
Other biosimilars and novel antibiotics like EMROK, EMROK O, Miqnaf, and Foviscu completed late-stage clinical trials with multiple new product filings, approvals, and launches during the quarter.
Highlights
- Wockhardt’s Q2 FY27 revenue increased by 24% year-over-year to Rs. 969 crore.
- Reported PAT was Rs. 73 crore for Q2 FY27, with half-year profit at Rs. 180 crore.
- Biotech segment revenues grew 68% in Q2 and 87% in H1 FY27, led by emerging markets.
- Emerging Markets revenue grew 52% in Q2 to Rs. 310 crore.
- India branded business grew 8% in Q2 to Rs. 146 crore; UK market grew 4% to GBP 28 million.
- Zaynich approved by US FDA in May 2026, under EMA review for multiple indications.
Key Data Snapshot
Financial performance
- Wockhardt reported Q2 FY27 revenue of Rs. 969 crore, up 24% from Rs. 782 crore in Q2 FY26.
- EBITDA for Q2 FY27 was Rs. 165 crore with 17.0% margin; excluding pre-launch expenses for Zaynich, EBITDA was Rs. 201 crore with 20.8% margin.
- Half year FY27 revenue was Rs. 1,898 crore, up 25% versus previous year, with EBITDA up 35% to Rs. 353 crore.
- PAT for Q2 FY27 was Rs. 73 crore, slightly lower than Rs. 82 crore in the prior year quarter, and half yearly PAT was Rs. 180 crore compared to a loss of Rs. 26 crore previously.
Operational performance
- Biotech operations recorded Rs. 252 crore revenue in Q2 FY27, up 68% year-over-year, and Rs. 487 crore in H1 FY27, up 87%.
- Emerging Market biotech segment grew approximately 110% in H1 FY27, benefiting from strategic partnerships and new deals across Brazil, Thailand, Egypt, Algeria, and LATAM.
- India branded business revenue grew 8% to Rs. 146 crore in Q2, driven by diabetic therapy, NCE EMROK, and regenerative derma segment.
- UK market revenue grew 4% year-over-year to GBP 28 million in Q2; Irish market grew 13% in H1 FY27 to EUR 11 million.
Business impact
- Zaynich, a novel antibiotic developed by Wockhardt, received US FDA approval in May 2026 for complicated urinary tract infections (cUTI), the first India-origin drug with this distinction.
- EMA regulatory review of Zaynich is ongoing with acceptance for review of multiple indications including cUTI, complicated intra-abdominal infections, hospital-acquired pneumonia, and bloodstream infections.
- Wockhardt completed Phase 3 clinical trials for five novel antibiotics including Emrok and Zaynich.
- Multiple new product filings, approvals, and launches occurred during the quarter, including 24 filings, 18 approvals, and 11 launches internationally, alongside biosimilars and new chemical entities.
- India approvals for EMROK O and EMROK injection were received for Uganda market entry.
Background and context
- Wockhardt is a pharmaceutical and biotechnology company operating across India, Emerging Markets, UK, and Ireland.
- The company targets growth in diabetes care with integrated biotech capabilities and focuses on expanding presence in emerging markets.
- The reported results are for the quarter and half year ended September 30, 2026, corresponding to Q2 and H1 FY27.
Highlights
- Wockhardt’s Q2 FY27 revenue increased by 24% year-over-year to Rs. 969 crore.
- Reported PAT was Rs. 73 crore for Q2 FY27, with half-year profit at Rs. 180 crore.
- Biotech segment revenues grew 68% in Q2 and 87% in H1 FY27, led by emerging markets.
- Emerging Markets revenue grew 52% in Q2 to Rs. 310 crore.
- India branded business grew 8% in Q2 to Rs. 146 crore; UK market grew 4% to GBP 28 million.
- Zaynich approved by US FDA in May 2026, under EMA review for multiple indications.
Disclosures
- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Bagmane Prime Office REIT Declares ₹5,270 Million Distribution and Reports ₹3,997.99 Million Profit for Q2 FY 2026-27
Bagmane Prime Office REIT declared a total distribution of ₹5,270 million or ₹1.55 per unit for the quarter ended September 30, 2026, comprising ₹1,122 million as interest and ₹4,148 million as dividend. The REIT also reported a profit of ₹3,997.99 million during this period and declared its net asset value at ₹113.61 per unit.
Read Full Story
TBO Tek Limited Reports 53% Revenue Growth and ₹152 Crore Adjusted EBITDA in Q2 FY27
TBO Tek Limited announced its Q2 FY27 consolidated financial results with revenue rising 53% year-on-year to ₹866 crore and adjusted EBITDA increasing 47% to ₹152 crore, supported by broad-based growth across India, APAC, Europe, North America, and a notable recovery in its Middle East business.
Read Full Story
Amara Raja Energy & Mobility Reports ₹250.71 Crore Profit Before Tax and 13% Revenue Growth in Q2 FY27
Amara Raja Energy & Mobility Limited reported a profit before tax of ₹250.71 crore and a 13% increase in revenue to ₹3,843.25 crore for the quarter ending September 30, 2026 (Q2 FY27), also announcing an interim dividend of ₹4.30 per equity share.
Read Full Story
